menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    WuXi Biologics Wins CDMO Leadership Awards 8th Year

    PR NEWSWIRE

    WuXi Biologics Again Passed GMP Inspection by Japan PMDA

    PR NEWSWIRE

    WuXi Biologics Wins Platinum Medal from EcoVadis for 2nd Year

    PR NEWSWIRE

    WuXi Biologics Named ESG Top-Rated Company by Morningstar

    PR NEWSWIRE

    Cirius to Present at WuXi Forum During J.P. Morgan Week

    PR NEWSWIRE

    Candid steps up TCE deal momentum with $925M WuXi partnership

    BUSSINESSWIRE

    WuXi Biologics to sell Irish vaccine site to Merck for $500M

    ENDPTS

    China`s WuXi to sell Advanced Therapies unit amid US restrictions

    REUTERS

    WuXi Hits Milestones with 16,000L PPQ and GMP Authorizations

    PR NEWSWIRE

    WuXi Biologics Germany Expands with Prefilled Syringe Line

    PR NEWSWIRE

    WuXi Biologics Earns AAA MSCI ESG Rating For Second Year

    PRESS RELEASE

    WuXi Biologics Launches WuXia™ RidGS for Cell Line Development

    PR NEWSWIRE

    WuXi Biologics Wins ESG Platinum Award Fourth Year In Row

    PRESS RELEASE

    China`s WuXi Explores Sale Of Pharma Operations As US Restrictions

    REUTERS

    WuXi Biologics Included in Hang Seng ESG 50 Index

    PR NEWSWIRE

    WuXi Completes First Scale-Up Of 2,000L WuXiUITM Bioprocess

    PRESS RELEASE

    WuXi Biologics Reports Solid 2024 Interim Results

    PRESS RELEASE

    Medigene And WuXi Biologics Enter Research Collaboration

    GLOBENEWSWIRE

    WuXi Bio gains some traction in Europe in the face of Biosecure threat in the US

    ENDPTS

    WuXi Biologics In S&P Sustainability Yearbook 2024 (China)

    PRESS RELEASE

    WuXi Biologics Facilities Recertified By EMA

    PR NEWSWIRE

    WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year

    PR NEWSWIRE

    WuXi shares jump after BIOSECURE`s exclusion from defense bill

    FIERCE PHARMA

    AGC Biologics, BioConnection forge partnership to be an alternative to WuXi

    ENDPTS

    U.S. Biosecure Act Advances with Revised Timeline

    CONTRACT PHARMA

    New bill sets decoupling deadline for industry`s work with WuXi

    FIERCE PHARMA

    WuXi Bio pulls out of 2024 BIO convention

    FIERCE PHARMA

    WuXi Biologics 2023 ESG Report Shows Sustainability Commitment

    PR NEWSWIRE

    Drug and biotech companies join lobbying push on China bill as scrutiny of WuXi

    ENDPTS

    WuXi Biologics Reports Solid 2023 Annual Results

    PR NEWSWIRE

    Hunting for ‘certainty and stability,’ WuXi Bio spotlights client relationships

    ENDPTS

    Biotech trade association to split with China`s WuXi AppTec

    REUTERS

    WuXi Biologics Achieves Leadership Level in 2023 CDP Climate Change Assessment

    PR NEWSWIRE

    WuXi Biologics Ireland Site Receives Three ISO Certifications

    PRESS RELEASE

    WuXi Biologics Recognized As ESG Top-Rated By Morningstar Sustainalytics

    PRESS RELEASE

    Lawmakers’ explosive charges turn a global spotlight on China’s WuXi

    ENDPTS

    WuXi AppTec, Wuxi Biologics plunge to multi-year lows on fears over biotech bill

    REUTERS

    WuXi Biologics Successfully Completes First 16,000L Manufacturing Run in Ireland

    PR NEWSWIRE

    WuXi Biologics Launches WuXiaADCC PLUSâ„¢ For Enhanced Antibodies

    PRESS RELEASE

    WuXi Biologics Launches WuXia ADCC PLUS™

    PR NEWSWIRE

    WuXi Biologics Granted US Patent For WuXiBodyâ„¢ Bispecific Platform

    PRESS RELEASE

    WuXi Biologics CEO Presents At J.P. Morgan Healthcare Conference

    PRESS RELEASE

    WuXi Biologics Signs Research Agreement With BioNTech For Antibodies

    PRESS RELEASE

    WuXi Bio expands US presence; FujiFilm boosts autoinjector services

    ENDPTS

    BioNTech pays WuXi $20M for 2 preclinical monoclonal antibodies

    FIERCE BIOTECH

    WUXI BIOLOGICS TO PARTICIAPTE AT 42nd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

    PRESS RELEASE

    WuXi Biologics to Increase Manufacturing Capacity in Massachusetts

    PRESS RELEASE

    WuXi Biologics, WuXi AppTec plot expansions in US, China

    FIERCE PHARMA

    WuXi Vaccines Wins Second Consecutive "Best Vaccine CMO Award" at AVEA 2023

    PR NEWSWIRE

    WuXi Vaccines Passes First GMP Audit by a Global Vaccine Leader

    PR NEWSWIRE

    WuXi Bio struggles amid CDMO industry downturn, stock plummets

    FIERCE PHARMA

    WuXi ImplementedProcess with a Breakthrough Productivity of ~6 g/L/day

    PR NEWSWIRE

    WuXi XDC Successfully Listed on the Main Board of Hong Kong Stock Exchange

    PR NEWSWIRE

    WuXi Biologics Receives AAA MSCI ESG Rating

    PR NEWSWIRE

    WuXi XDC to funnel IPO proceeds into manufacturing expansions

    FIERCE PHARMA

    WuXi TIDES boosts oligo, peptide offerings

    ENDPTS

    WuXi XDC and HKSTP Join Forces to Promote Development of Bioconjugate Drug

    PR NEWSWIRE

    IMIDomics Announces Strategic Agreement with WuXi Biologics

    BUSINESSWIRE

    BioNTech reiterates presence in Africa; WuXi eyes first Chinese vaccine plant

    ENDPTS

    WuXi Vaccines Launches Its First Vaccines CDMO Site in China

    PR NEWSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.